The aim of these short and practical video productions is to improve knowledge of Rift Valley fever and its control measures. To further encourage local communities to participate in surveillance and programs working to better prevent or control the disease, the videos have also been prepared in Swahili.
Three doses of p67C antigen generated stronger immune responses than two doses. Antibody titres and CD4+ T-cell proliferation correlated with protection against East Coast fever. The number of doses could not be reduced from three to two without compromising the protection.
To support research on the biology of T. parva and the identification of additional candidate vaccine antigens, this article reports on the sporozoite proteome as defined by LC–MS/MS analysis.
Originally posted on ILRI news:
Over the past several weeks, illegal attempts to grab land have escalated at Kapiti Plains Estate (now known as Kapiti research station), located about 60 km southeast of Nairobi along Mombasa Road, in Kenya’s Machakos County. Members of groups involved in the illegal sales have started trespassing and building illegal structures on…
There is inadequate herd and community level information on the impact of CBPP and its control by vaccination to allow adequate allocation of resources for CBPP control in affected ecosystems of Kenya. A study was designed in Narok district to provide this crucial information for the Maasai ecosystem.
The ECF consortium is aiming at producing a vaccine that would trigger both an antibody response and a T cell dependent response. Thanks to the whole genome sequence of Theileria parva and its annotation, we have short listed hundreds of antigen candidates, but the number of antigen candidate that can be tested in cattle is limited. How do we narrow down the list of candidates to a handful that can be studied rigorously in live experiments?
The recent meeting of the East Coast fever consortium, which brings together experts in immunology, parasitology and genomics from three continents (ILRI, Edinburgh, Antwerp, IGS, as well as the organization that produces the infection and treatment method (ITM) vaccine, provided a venue to discuss a way forward.